Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

Dosing Reliability of Direct Thrombin Inhibitors in Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis
Wieruszewski, Patrick M. , Brinkman, Hannah M. , Ripoll, Juan G. , Pieterick, Sarah E., Damico, Katharine, Wittwer, Erica D. , Gerberi, Dana , Ursoleo, Jacopo D’Andria , Wieruszewski, Erin D. , Seelhammer, Troy G. , Normand, Sarah , Damico, Katharine E, Wieruszewski, Patrick M , D'Andria Ursoleo, Jacopo , Pieterick, Sarah E , Ortoleva, Jamel P. , Chatterjee, Subhasis

ASAIO Journal | July 17, 2025 | Volume: 71 | Issue: 9 | Pages: 691-700

10.1097/mat.0000000000002512 | PMID 40673548 Get It

Empirical evidence suggests direct thrombin inhibitors (DTIs) produce more favorable hemostatic outcomes than heparin in patients supported by extracorporeal membrane oxygenation (ECMO), yet the exact mechanisms responsible are unknown. We systematically searched databases and registers for studies comparing DTIs to heparin in humans receiving ECMO. A total of 28 studies were identified, most of which (n = 25) used bivalirudin, while the rest (n = 3) used argatroban. In random-effects meta-analysis, DTIs achieved the therapeutic anticoagulation range faster (mean difference = −6.96 hours, 95% confidence interval [CI] = −11.98 to −1.95, p = 0.006) and maintained the therapeutic range for a greater proportion of time (mean difference = 18.6%, 95% CI = 8.78–28.42, p < 0.001) than heparin. Subgroup analysis revealed these effects were similarly significant in adult patients and when bivalirudin was the DTI; however, they were not significant in pediatric patients or when argatroban was the DTI. Sensitivity analysis confirmed robustness of the primary findings in only low-risk of bias studies and in only studies published as full papers. In summary, DTIs—specifically bivalirudin—were associated with faster time to therapeutic anticoagulation and maintained the goal range for a greater percentage of time than heparin during ECMO support.
Heterogeneity of Cardiovascular Effects of Second‐Line Glucose‐Lowering Therapies in Adults With Type 2 Diabetes Across the Range of Moderate Baseline Cardiovascular Risk
Deng, Yihong , Herrin, Jeph , Swarna, Kavya, Kent, David M. , Ross, Joseph S. , Maron, Bradley A. , Mickelson, Mindy M. , McCoy, Rozalina G. , Herrin, Jeph , Swarna, Kavya S, Kent, David M , Ross, Joseph S , Maron, Bradley A , Mickelson, Mindy M , McCoy, Rozalina Grubina , Deng, Yihong , Polley, Eric C.

Journal of the American Heart Association | July 17, 2025 | Volume: 14 | Issue: 15 | Pages: No page available

10.1161/jaha.124.040217 | PMID 40673553 Get It

Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and sodium–glucose cotransporter‐2 inhibitors (SGLT2is) have favorable cardiovascular outcomes compared with dipeptidyl peptidase‐4 inhibitors (DPP4is) and sulfonylureas in adults with type 2 diabetes and high cardiovascular risk. How these benefits vary across lower levels of cardiovascular risk is unknown. Methods We used nationwide claims data to emulate a comparative effectiveness trial and examine the heterogeneity of treatment effects of GLP‐1RAs, SGLT2is, DPP4is, and sulfonylureas on major adverse cardiovascular events (MACEs) among adults with type 2 diabetes and moderate cardiovascular risk (annualized MACE risk 1%–5%, estimated using the annualized claims‐based MACE estimator). Results Among 386 276 included adults with type 2 diabetes, 25.2% had baseline ACME–predicted MACE risk >1% to ≤2% (lower‐risk patients) and 13.3% had ACME–predicted risk >4% to ≤5% (higher‐risk patients). By year 3 of treatment, higher‐risk patients derived greater absolute benefit than lower‐risk patients when treated with GLP‐1RAs versus sulfonylureas (absolute reduction in the estimated rate of MACE of 3.1% in higher‐risk patients and 1.6% in lower‐risk patients), SGLT2is versus sulfonylureas (absolute reduction, 3.9% in higher‐risk patients and 1.3% in lower‐risk patients), and GLP‐1RAs versus DPP4is (absolute reduction, 1.6% in higher‐risk patients and 0.5% in lower‐risk patients). The relative benefits for MACE were also greater in higher‐risk than lower‐risk patients with SGLT2is versus DPP4is (hazard ratio [HR], 0.78 [95% CI, 0.70–0.87] in higher‐risk patients; HR, 0.99 [95% CI, 0.88–1.12] in lower‐risk patients). Conversely, the relative benefits of DPP4is and GLP‐1RAs versus sulfonylureas were greater in lower‐risk patients: HR 0.76 (95% CI, 0.71–0.81) in lower‐risk and HR 0.91 (95% CI, 0.97–0.96) in higher‐risk patients for DPP4is versus sulfonylureas; HR 0.67 (95% CI, 0.58–0.78) in lower‐risk and HR 0.80 (95% CI, 0.70–0.93) in higher‐risk patients for GLP‐1RAs versus sulfonylurea. Benefits of SGLT2is and GLP‐1RAs were comparable across all risk levels. Conclusions Cardiovascular benefits of SGLT2is and GLP‐1RAs exist across all levels of moderate cardiovascular risk, reinforcing the importance of choosing glucose‐lowering therapies that can prevent MACE in all people with type 2 diabetes.
Reply to: “Before Coming to the Conclusion That Inclusion Body Myositis Is a Risk Factor for a Heart Attack, All Influencing Factors Must Be Taken Into Account”
Naddaf, Elie , Naddaf, Elie

European Journal of Neurology | July 17, 2025 | Volume: 32 | Issue: 7 | Pages: No page available

10.1111/ene.70295 | PMID 40673444 Get It

Development of a Trauma Screening Pathway for Youth and Their Primary Caregiver Undergoing Bone Marrow Transplant: A Feasibility Study
Khatami, Emma H. , Manson, Megan A., Shaw, Tressia, Adams, Roberta H.

Clinical Practice in Pediatric Psychology | July 17, 2025 | Volume: 13 | Issue: 4 | Pages: 363-372

10.1177/21694826251359661 Get It

Hematopoietic stem cell transplantation (HSCT) is a lifesaving intervention for various hematologic and oncologic diseases that presents significant psychological risks for pediatric patients and their caregivers. Implementation of a longitudinal screening pathway for associated symptoms of post-traumatic stress disorder (PTSD) has been recommended; however, feasibility and utility in directing behavioral health needs remains unclear. Patients’ eligibility for enrollment included scheduled allogeneic or autologous HSCT through our institution’s Center for Cancer and Blood Disorders. Eligible caregivers and patients completed psychometrically validated self-report instruments assessing PTSD symptoms via REDCap pre-transplant, at 30 days, 100 days, 180 days, and 365 days following transplant. Individuals who reported experiencing clinically significant trauma symptoms at any timepoint were referred to a mental health clinician for treatment. If already involved in therapy, session frequency was recommended to increase and trauma-focused interventions were prioritized. Between April 2022 and April 2024, approximately 90% of eligible patients and caregivers consented for study participation ( N = 62). Preliminary findings suggest excellent retention and participants represented a diverse sample. Additionally, based on screening results at each timepoint, approximately 70% of our sample was connected to mental health services or offered increased session frequency if already engaged in treatment based on screening results. HSCT reflects a stressful experience for both patients and their caregivers. Systematically screening for PTSD among this population at the time of transplant and throughout the subsequent year was feasible and enabled targeted provision of behavioral health services.
NRG Oncology Liver Proton SBRT and Hypofractionated Radiation Therapy: Current Treatment Technical Assessment and Practice Patterns
Kang, Minglei , Taylor, Paige A. , Shen, Jiajian , Saini, Jatinder, Hong, Theodore S. , Liu, Wei , Xiao, Ying , Simone, Charles B. , Lin, Liyong , Liu, Wei , Xiao, Ying , Simone, Charles B , Lin, Liyong , Taylor, Paige , Shen, Jiajian , Zhou, Jun , Higgins, Kristin Ann

Cancers | July 17, 2025 | Volume: 17 | Issue: 14 | Pages: 2369

10.3390/cancers17142369 | PMID 40723252 Get It

Background/Objectives: Proton therapy delivers highly conformal doses to the target area without producing an exit dose, minimizing cumulative doses to healthy liver tissue. This study aims to evaluate current practices, challenges, and variations in the implementation of proton stereotactic body radiation therapy (SBRT) and hypofractionated therapy for liver malignancies, with the goal of providing a technical assessment to promote broader adoption and support future clinical trials. Methods and Materials: An extensive survey was conducted by NRG Oncology across North American proton treatment centers to assess the current practices of proton liver SBRT and hypofractionated therapy. The survey focused on key aspects, including patient selection, prescription and normal tissue constraints, simulation and motion management, treatment planning, quality assurance (QA), treatment delivery, and the use of image-guided radiation therapy (IGRT). Results: This survey captures the current practice patterns and status of proton SBRT and hypofractionated therapy in liver cancer treatment. Proton therapy is increasingly preferred for treating inoperable liver malignancies due to its ability to minimize healthy tissue exposure. However, the precision required for proton therapy presents challenges, particularly in managing uncertainties and target motion during high-dose fractions and short treatment courses. Survey findings revealed significant variability in clinical practices across centers, highlighting differences in motion management, dose fractionation schedules, and QA protocols. Conclusion: Proton SBRT and hypofractionated therapy offer significant potential for treating liver malignancies. A comprehensive approach involving precise patient selection, treatment planning, and QA is essential for ensuring safety and effectiveness. This survey provides valuable insights into current practices and challenges, offering a foundation for technical recommendations to optimize the use of proton therapy and guide future clinical trials.
Clinical evaluation of adults undergoing elective surgery utilizing intraoperative incisional wound irrigation (CLEAN Wound): protocol for a randomised controlled trial
Roke, Rachel , Lillie, Erin , Daneman, Nick , Mason, Stephanie, Jiang, Yidi , Shiroky, Jonah , Puran, Sudarshani, Smith, David E. , Khalil, Jad Abou, Kayssi, Ahmed , Pinchuk, Brian, Apte, Sameer , Lamb, Tyler , Ma, Grace , Vogt, Kelly, Leslie, Kenneth , Mutabdzic, Dorotea, Gómez, David , Ladha, Karim S. , Bennett, Sean, Ullah, Shahnoor M, Holland, Jessica, Smith, Andrew J., Calderone, Michael, Herriott, Judith, Voltan, Ed, Sloan, B., Mazer, C. David , Kennedy, Erin, Aarts, Mary-Anne, Karanicolas, Paul J. , Kayssi, Ahmed , Apte, Sameer S , Lamb, Tyler , Delisle, Megan , Muaddi, Hala , Fergusson, Dean A , Marshall, John C. , Karanicolas, Paul Jack , Tomlinson, George , Serrano, Pablo E , Vogt, Kelly, Tsang, Melanie E. , Ullah, Shahnoor M, Nathens, Avery B.

BMJ Open | July 17, 2025 | Volume: 15 | Issue: 7 | Pages: e104375

10.1136/bmjopen-2025-104375 | PMID 40675632 Get It

Introduction In moderate to high-risk surgical procedures, 15–25% of patients develop a postoperative surgical site infection. Intraoperative incisional wound irrigation has the potential to reduce surgical site infections, and additional randomised controlled trials are required to provide evidence of effectiveness. Methods and analysis This protocol describes a pragmatic, adaptive, participant and adjudicator-blinded trial at 13 sites in Canada in up to 2500 participants. Participants planned for surgery with an abdominal or groin incision, who are eligible and provide verbal consent through an integrated consent model, are randomised to receive intraoperative incisional wound irrigation with povidone-iodine, saline or no irrigation. The primary outcome is surgical site infection within 30 days postoperatively. Secondary outcomes include quality of life measured 30 days postoperatively and morbidity, mortality and healthcare utilisation within 90 days postoperatively. Ethics and dissemination This trial has been approved by the research ethics board at the participating centres and stopped enrolling participants on May 23, 2025. All participants will provide verbal consent. Results will be disseminated via presentation at conferences, publication and posted on clinicaltrials.gov. Trial registration number The study is registered with http://clinicaltrial.gov ( NCT04548661 ; 14 September 2020).
Chronic lymphocytic lymphoma complicated by Mycobacterium avium and Scedosporium apiospermum
Sivasubramaniam, Dhiran, Kalyanasundaram, Bala Vignesh , Palanisamy, Nithish Nanda, Nagaraju, Sivakumar, Nanda Palanisamy, Nithish

European Journal of Case Reports in Internal Medicine | July 17, 2025 | Volume: 12 | Issue: 8 | Pages: No page available

10.12890/2025_005621 | PMID 40786553 Get It

Introduction: Chronic lymphocytic leukaemia (CLL), the most common adult leukaemia in Western countries, poses unique management challenges, particularly when complicated by opportunistic infections. This report presents a rare case of CLL with concurrent Mycobacterium avium and Scedosporium apiospermum infections—pathogens increasingly recognized for causing severe disease in immunocompromised individuals. Their coexistence highlights the need for heightened awareness of diverse infectious complications in CLL patients. Case description: We present a case of a 78-year-old male with CLL receiving chemotherapy, who developed burning pain in the tongue and oral mucosa, accompanied by a non- productive cough. He was initially diagnosed with pneumonia, but further investigation revealed co-infection involving M. avium and S. apiospermum. Discussion: The coexistence of M. avium and S. apiospermum underscores the complexity of infectious complications in CLL. The patient’s chemotherapy was halted due to active pneumonitis observed on imaging in order to improve his leukocyte count. Antifungal therapy was not initiated due to a lack of evidence of invasive fungal infection. Antimycobacterial therapy for M. avium complex was initiated. Conclusion: This case highlights the necessity of a multidisciplinary approach and continued research to optimize management strategies and improve outcomes in CLL patients with dual infections.
Transbronchial cryobiopsy to diagnose diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH)
Chand, Arista , Filsoof, Darius, Manchen, Peter , Soin, Sabrina, Soin, Sabrina

BMJ Case Reports | July 17, 2025 | Volume: 18 | Issue: 7 | Pages: e266666

10.1136/bcr-2025-266666 | PMID 40675655 Get It

Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare precursor of neuroendocrine malignancy. Diagnosis is difficult as clinical and radiological findings can be non-specific. Histological confirmation is necessary, and surgical lung biopsy is still considered the gold standard technique to aid multidisciplinary discussion. There are increasing reports of using transbronchial lung cryobiopsy (TBLC) for tissue sampling, allowing a feasible and safe alternative to diagnosis. Here we present a case of cough, dyspnoea and hypoxia in a woman ultimately diagnosed with DIPNECH using TBLC.
Expanding the Cutaneous Presentation of Blau Syndrome, Response to Treatment, and Correlation With Genetics
Aghazadeh, Nessa , Mittal, Setu , Orandi, Amir B. , Smith, Wendy M. , Khan, Nila S., Davis, Dawn Marie R. , Davis, Dawn M R , Orandi, Amir B , Aghazadeh Mohandesi, Nessa , Mittal, Setu , Khan, Nila S.

Pediatric Dermatology | July 17, 2025 | Volume: 42 | Issue: 5 | Pages: 956-960

10.1111/pde.15994 | PMID 40667856 Get It

ABSTRACTBackgroundBlau syndrome is a rare, autosomal dominant granulomatous disease caused by mutations in the NOD2/CARD15 gene. While the classic triad of arthritis, dermatitis, and uveitis is well known, the full range of cutaneous manifestations remains underexplored.ObjectiveTo expand the understanding of cutaneous findings in Blau syndrome, correlate these findings with NOD2 variants, and evaluate treatment outcomes across organ systems.MethodsA retrospective review of medical records from January 1999 to January 2024 identified 14 patients with Blau syndrome supported by the presence of NOD2 variants. Clinical data on dermatological features, genetics, and treatment responses were analyzed and categorized into specific and non‐specific cutaneous findings.ResultsOf the 14 patients with Blau syndrome, 85% (12/14) demonstrated skin involvement. Specific findings included lichenoid or granulomatous papules and nodules (50%, 6/12), while non‐specific findings (83%, 10/12) were more diverse, including dermatitis (6/10), chronic urticaria (5/10), ichthyosiform eruptions (4/10), vasospastic disorders (5/10), and oral/genital ulcers (2/10). Skin biopsies in three patients with specific findings revealed non‐caseating granulomas. Genetic analysis identified multiple NOD2 variants, though no clear genotype–phenotype correlation was observed. TNF‐alpha inhibitors demonstrated efficacy in controlling ocular and joint disease.ConclusionBlau syndrome presents with a broader spectrum of cutaneous findings than previously recognized. These findings highlight the importance of dermatological evaluation and a multidisciplinary approach to optimize diagnosis and management.
Rectus sheath hematoma causing cecal perforation: a case report
Awad, Amir, Meagher, Mitchell, Theerman, Isaac, Beckermann, Jason , Awad, Abanoub, Beckermann, Jason , Awad, Abanoub A

Journal of Surgical Case Reports | July 17, 2025 | Volume: 2025 | Issue: 7 | Pages: No page available

10.1093/jscr/rjaf550 | PMID 40678159 Get It

Abstract Rectus sheath hematoma is a rare condition caused by bleeding from the epigastric arteries, with an incidence of 1.2–1.5 cases per year. We present a 49-year-old male with a smoking history and recent corona virus disease 2019 (COVID-19) infection who presented with symptoms of an upper respiratory infection and suspected venous thromboembolism. Imaging revealed bilateral pulmonary emboli and a left rectus sheath hematoma, which was initially managed conservatively. However, the patient’s condition worsened with a significant drop in hemoglobin and development of encephalopathy. Imaging showed an enlarging hematoma, leading to transfusion and selective embolization. On day 8, the patient developed generalized abdominal pain, and imaging confirmed a hollow viscus perforation. An exploratory laparotomy revealed cecal perforation due to mass effect from the hematoma. An ileocecectomy was performed.